OptimizeRx Announces Pricing of Public Offering of Common Stock
18 Dezember 2018 - 2:52PM
OptimizeRx Corporation (Nasdaq: OPRX), a leading provider of
digital health messaging for the pharmaceutical industry, today
announced the pricing of the previously announced underwritten
public offering by WPP Luxembourg Gamma Three S.à r.l., a
shareholder of OptimizeRx, of 2,103,702 shares of OptimizeRx common
stock, at a public offering price of $10.00 per share. In
connection with the offering, OptimizeRx granted the underwriters a
30-day option to purchase up to an additional 315,555 newly issued
shares of common stock from the Company at the public offering
price less the underwriting discount and commissions. The offering
is expected to close on or about December 20, 2018, subject to
customary closing conditions.
OptimizeRx will not receive any proceeds from the sale of the
shares by the selling shareholder. If the underwriters’ option to
purchase up to the additional 315,555 shares of common stock
offered by OptimizeRx is exercised in full, OptimizeRx would
receive net proceeds of approximately $2.9 million, which will be
used by the Company for working capital and other general corporate
purposes.
William Blair & Company, L.L.C. and B. Riley FBR, Inc. are
the joint book-running managers for the offering.
Roth Capital Partners, LLC and Lake Street Capital Markets, LLC
are acting as the financial advisors for the offering.
The shares of common stock described above are being offered
pursuant to a shelf registration statement on Form S-3 (File No.
333-228357) that was originally filed with the Securities and
Exchange Commission (the “SEC”) on November 13, 2018 and declared
effective by the SEC on December 11, 2018. A preliminary
prospectus supplement relating to and describing the terms of the
offering was filed with the SEC and is available on the
SEC’s website at http://www.sec.gov. A final prospectus
supplement and the accompanying base prospectus relating to the
offering and the shares of common stock being offered will be filed
with the SEC. Copies of the registration statement, the final
prospectus supplement and the accompanying base prospectus may be
obtained on the SEC’s website at http://www.sec.gov or, when
available, from William Blair & Company, L.L.C., Attention:
Prospectus Department, 150 North Riverside Plaza, Chicago, IL
60606; Phone: (800) 621-0687; Email: prospectus@williamblair.com;
and from B. Riley FBR, Inc., Attention: Syndicate Prospectus
Department, 1400 North 17th Street, Suite 1300, Arlington, VA
22209; Phone: (703) 312-9580; Email:
prospectuses@brileyfbr.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About OptimizeRx
OptimizeRx® (Nasdaq: OPRX), a digital health company, connects
pharmaceutical companies to patients and providers, offering
greater affordability, adherence and brand awareness at the
point-of-care. As the nation’s largest point-of-prescribe
promotional platform for the pharmaceutical industry, OptimizeRx
provides a direct channel for pharma companies to communicate with
healthcare providers right within their workflow. The cloud-based
solution supports patient adherence to medications with real-time
access to financial assistance, prior authorization, education and
critical clinical information. OptimizeRx provides more than half
of the ambulatory patient market with access to these benefits
through leading EHR platforms like Allscripts, Amazing Charts and
Quest. The Company’s mobile messaging platform also supports
direct, real-time communication to patients for improved medication
adherence, affordability, and healthcare outcomes.
Important Cautions Regarding Forward-Looking
Statements
Certain information contained in this press release includes
“forward-looking statements” within the meaning of The Private
Securities Litigation Reform Act of 1995, including statements
related to the proposed public offering, the filing of the
registration statement and potential market opportunity for our
product candidates. We may, in some cases use terms such as
“predicts,” “believes,” “potential,” “continue,” “anticipates,”
“estimates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should” or other words that convey uncertainty of
the future events or outcomes to identify these forward-looking
statements. Our forward-looking statements are based on current
expectations that involve risks, potential changes in
circumstances, assumptions and uncertainties. Any or all of the
forward-looking statements may turn out to be wrong, or be affected
by inaccurate assumptions we might make or by known or unknown
risks and uncertainties as a result of various important factors,
including the uncertainties related to market conditions, our
ability to satisfy the closing conditions of the offering, the
timing or occurrence of the closing, and the anticipated use of the
proceeds of the offering, which could change as a result of market
conditions or for other reasons. For a further description of
the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to our business in general, please refer to
our prospectus supplement filed with the Securities and Exchange
Commission (SEC) on December 17, 2018 under the heading “Risk
Factors” and those documents incorporated by reference therein,
which includes our Annual Report on Form 10-K filed with the SEC on
March 8, 2018. You are cautioned not to place undue reliance on
these forward-looking statements, which are made only as of the
date of this press release. We undertake no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstances.
OptimizeRx ContactDoug Baker, CFOTel (248)
651-6568 x807dbaker@optimizerx.com
Media Relations ContactNicole Brooks, Innsena
Communications(Tel) 860-800-2344nicolebrooks@innsena.com
Investor Relations ContactRon Both, CMATel
(949) 432-7557oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024